Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

Author： Murthy Rashmi K. Varma Ankur Mishra Priyankana Hess Kenneth R. Young Elliana Murray James L. Koenig Kimberly H. Moulder Stacy L. Melhem-Bertrandt Amal Giordano Sharon H. Booser Daniel Valero Vicente Hortobagyi Gabriel N. Esteva Francisco J.

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|13|1932-1938

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.13, 2014-07, pp. : 1932-1938

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Neoadjuvant docetaxel, vinorelbine and trastuzumab prior to surgery and adjuvant therapy is active in patients with HER-2 breast cancer

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Neoadjuvant trastuzumab + FEC for HER2-positive breast cancer

Inpharma, Vol. 1, Iss. 1485, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S. Perry Caroline M.

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio Mottolese Marcella Fabi Alessandra

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe Bettio Daniela Torri Valter Masci Giovanna Salvini Piermario Santoro Armando

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite